| ZTS |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.87 vs. cons $1.84 |
MEDIUM |
| ZTS |
Report |
Total revenue |
IN-LINE |
pred ~$2.50B vs. cons $2.49B |
MEDIUM |
| ZTS |
Report |
Organic operational revenue growth |
MISS |
pred ~1.0% vs. cons 1.6% |
MEDIUM |
| ZTS |
Guide |
Revenue guidance |
BETTER |
guide ~$9.76B vs. cons $9.72B (FY2026) |
MEDIUM |
| ZTS |
Guide |
Adjusted diluted EPS guidance |
BETTER |
guide ~$6.93 vs. cons $6.89 (FY2026) |
MEDIUM |
| ZTS |
Guide |
Organic operational revenue growth guidance |
LOWER |
guide ~3.0% vs. cons 3.3% (FY2026) |
MEDIUM |
| ZTS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.8% |
— |
MEDIUM |
| ZTS |
Return |
5-day cumulative residual |
+1.7% (FADE) |
Day-5 residual ~+1.7% vs. day-1 residual ~+4.8%: an EPS beat, stabilization signals and guidance numerically above consensus should drive initial relief, but a lower organic-growth midpoint and weaker implied second-half companion-animal trajectory should pull out-period estimates down and partially reverse the move. |
MEDIUM |